Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome

被引:63
作者
Krcmery, V
Oravcova, E
Spanik, S
Mrazova-Studena, M
Trupl, J
Kunova, A
Stopkova-Grey, K
Kukuckova, E
Krupova, I
Demitrovicova, A
Kralovicova, K
机构
[1] Univ Trnava, Dept Med, Trnava, Slovakia
[2] Postgrad Med Sch, Dept Chemotherapy, Bratislava, Slovakia
[3] NCI, Dept Microbiol, Bratislava, Slovakia
[4] St Elizabeths Canc Inst, Dept Pharmacol, Bratislava, Slovakia
关键词
D O I
10.1093/jac/41.3.373
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Forty-one episodes of breakthrough fungaemia occurring over a 7.5 year period in the National and St Elizabeth's Cancer Institutes in Bratislava, Slovakia, were analysed. Five of them occurred during prophylaxis with fluconazole tone Torulopsis glabrata, one Hansenula anomala, two Candida krusei and one Candida parapsilosis), ten with itraconazole (three Trichosporon pullulans, one Trichosporon beigelii, one Cryptococcus laurentii, three Candida albicans and two T. glabrata), 11 during prophylaxis with ketoconazole (one Candida norvegenesis, one C. parapsilosis, one C. krusei, one Candida tropicalis, five C. albicans, one Candida stellatoidea and one C. laurentii and 15 during empirical therapy with amphotericin B (ten C. albicans, two T. beigelii and three Candida lusitaniae). The most frequent risk factors for breakthrough fungaemia were neutropenia, previous therapy with multiple antibiotics and recent catheter insertion. Comparing these episodes with 38 non-breakthrough fungaemias (appearing at the same institute in the same period) differences in certain risk factors were noted: breakthrough fungaemias were more frequently observed in patients with acute leukaemia (39.0% vs 5.2%, P < 0.001), mucositis (34.2% vs 13.1%, P < 0.05), prophylaxis with quinolones (58.5% vs 15.8%, P < 0.0001) and catheter-associated infections (29.3% vs 2.6%, P < 0.003). In this subgroup overall mortality (36.6% vs 28.8%) or early attributable mortality (22.0% vs 23.6%) were not significantly different.
引用
收藏
页码:373 / 380
页数:8
相关论文
共 21 条
  • [1] BONOTTE B, 1995, PROGRAMME NEW TRENDS, P54
  • [2] BROUGHTON MC, 1991, MYCOSES, V34, P75, DOI 10.1111/j.1439-0507.1991.tb00623.x
  • [3] DUPONT B, 1994, CURRENT OPINION INFE, V3, P78
  • [4] A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    GOODMAN, JL
    WINSTON, DJ
    GREENFIELD, RA
    CHANDRASEKAR, PH
    FOX, B
    KAIZER, H
    SHADDUCK, RK
    SHEA, TC
    STIFF, P
    FRIEDMAN, DJ
    POWDERLY, WG
    SILBER, JL
    HOROWITZ, H
    LICHTIN, A
    WOLFF, SN
    MANGAN, KF
    SILVER, SM
    WEISDORF, D
    HO, WG
    GILBERT, G
    BUELL, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) : 845 - 851
  • [5] GUIOT HFL, 1994, CLIN INFECT DIS, V18, P535
  • [6] INVASIVE INFECTION DUE TO CANDIDA-KRUSEI IN IMMUNOCOMPROMISED PATIENTS NOT TREATED WITH FLUCONAZOLE
    IWEN, PC
    KELLY, DM
    REED, EC
    HINRICHS, SH
    [J]. CLINICAL INFECTIOUS DISEASES, 1995, 20 (02) : 342 - 347
  • [7] AMPHOTERICIN-RESISTANT INVASIVE HEPATOSPLENIC CANDIDIASIS CONTROLLED BY FLUCONAZOLE
    JAKAB, K
    KELEMEN, E
    PRINZ, G
    TOROK, I
    [J]. LANCET, 1990, 335 (8687) : 473 - 474
  • [8] KROMERY V, 1997, CHEMOTHERAPY, V43, P113
  • [9] CANDIDA-GLABRATA, CANDIDA-KRUSEI, NON-ALBICANS CANDIDA SPP, AND OTHER FUNGAL ORGANISMS IN A 60-BED NATIONAL CANCER CENTER IN 1989-1993 - NO ASSOCIATION WITH THE USE OF FLUCONAZOLE
    KUNOVA, A
    TRUPL, J
    SPANIK, S
    DRGONA, L
    SUFLIARSKY, J
    LACKA, J
    STUDENA, V
    HLAVACOVA, E
    STUDENA, M
    KUKUCKOVA, E
    KOLLAR, T
    PICHNA, P
    ORAVCOVA, E
    KRCMERY, V
    [J]. CHEMOTHERAPY, 1995, 41 (01) : 39 - 44
  • [10] KUNOVA A, 1995, CHEMOTHERAPY, V42, P157